Sunshine Biopharma (SBFM) Capital Expenditures (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly Capital Expenditures came in at $5129.0 in Q1 2026, down 31.52% YoY from $7490.0 in Q1 2025, and up 593.65% on a QoQ basis from -$1039.0 in Q4 2025.
Sunshine Biopharma (SBFM) Capital Expenditures (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 11 years of Capital Expenditures data on file, last reported at $5129.0 in Q1 2026.
- Quarterly Capital Expenditures fell 31.52% year-over-year to $5129.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172130.0 (down 89.25% YoY) and the FY2025 annual result came in at $174491.0, down 89.47% from the prior year.
- Capital Expenditures rose to $5129.0 in Q1 2026, from -$1039.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $974513.0 in Q2 2024 to a low of -$382363.0 in Q4 2023.
- A 5-year average of $138160.7 and a median of $36285.5 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures slumped 297.11% — and 2024, when it soared 5266.46%.
- Tracing SBFM's Capital Expenditures over 5 years: stood at $193982.0 in 2022, then tumbled by 297.11% to -$382363.0 in 2023, then jumped by 126.83% to $102600.0 in 2024, then tumbled by 101.01% to -$1039.0 in 2025, then jumped by 593.65% to $5129.0 in 2026.
- The last three Capital Expenditures figures came in at $5129.0 (Q1 2026), -$1039.0 (Q4 2025), and $8040.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.36 Bn | 43.40 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.76 Bn | 40.11 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 32.39 Bn | 30.71 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.45 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.87 Bn | 17.99 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.64 Bn | 15.25 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.99 Bn | 11.46 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Sunshine Biopharma | 1.57 Mn | -12.18 Mn | 2.43 Mn | 7,015.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7,015.00 |
| Jun 30, 2026 | 7,015.00 |
| Mar 31, 2026 | 5,129.00 |
| Mar 31, 2026 | 5,129.00 |
| Dec 31, 2025 | -1,039.00 |
| Dec 31, 2025 | -1,039.00 |
| Sep 30, 2025 | 8,040.00 |
| Sep 30, 2025 | 8,040.00 |
| Jun 30, 2025 | 160,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Mar 31, 2025 | 7,490.00 |
| Mar 31, 2025 | 7,490.00 |
| Dec 31, 2024 | 102,600.00 |
| Dec 31, 2024 | 102,600.00 |
| Sep 30, 2024 | 517,005.00 |
| Sep 30, 2024 | 517,005.00 |
| Jun 30, 2024 | 974,513.00 |
| Jun 30, 2024 | 974,513.00 |
| Mar 31, 2024 | 62,937.00 |
| Mar 31, 2024 | 62,937.00 |